1. Home
  2. ANTX

as 05-21-2024 12:35pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.

Founded: 2017 Country:
United States
United States
Employees: 36 City: MENLO PARK
Market Cap: 66.5M IPO Year: 2022
Target Price: $5.00 AVG Volume (30 days): 326.1K
Analyst Decision: Hold Number of Analysts: 4
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.54 EPS Growth: N/A
52 Week Low/High: $2.20 - $22.22 Next Earning Date: 05-14-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks:

Stock Insider Trading Activity of AN2 Therapeutics Inc. (ANTX)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Adjuvant Global Health Technology Fund, L.P. ANTX 10% Owner Jan 16 '24 Sell $19.65 84,093 $1,652,427.45 1,995,958 SEC Form 4
Adjuvant Global Health Technology Fund, L.P. ANTX 10% Owner Jan 16 '24 Sell $19.65 15,907 $312,572.55 377,542 SEC Form 4
Readnour Robin Shane ANTX Director Jan 12 '24 Sell $21.91 719 $15,753.29 485,073 SEC Form 4
Readnour Robin Shane ANTX Director Jan 12 '24 Sell $21.92 706 $15,475.52 414,788 SEC Form 4
Readnour Robin Shane ANTX Director Jan 10 '24 Sell $21.92 1,800 $39,456.00 485,792 SEC Form 4
Readnour Robin Shane ANTX Director Jan 10 '24 Sell $21.93 1,869 $40,987.17 415,494 SEC Form 4
Krause Kevin Michael ANTX Chief Strategy Officer Jan 9 '24 Sell $20.14 7,417 $149,367.25 1,914 SEC Form 4
Krause Kevin Michael ANTX Chief Strategy Officer Jan 2 '24 Sell $20.12 2,583 $51,967.12 1,914 SEC Form 4
Adjuvant Global Health Technology Fund, L.P. ANTX 10% Owner Nov 14 '23 Sell $16.15 1,522 $24,574.21 2,080,051 SEC Form 4
Adjuvant Global Health Technology Fund, L.P. ANTX 10% Owner Nov 14 '23 Sell $16.15 288 $4,650.05 393,449 SEC Form 4